Allegra Franchise Adds Pediatric Oral Suspension
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis’ allergic rhinitis therapy is approved for seasonal allergies and idiopathic urticaria in children as young as 6 months.
You may also be interested in...
Alliant To Detail Allegra Oral Suspension
The two-year contract covers U.S. pediatricians and pediatric sub-specialties.
Alliant To Detail Allegra Oral Suspension
The two-year contract covers U.S. pediatricians and pediatric sub-specialties.
UCB’s Next Allergy Partner Is Sanofi-Aventis
Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.